ClinicalTrials.gg
RecruitingNCT06630819Updated May 29, 2025

Buccal Infiltration of Different Volumes of Articaine for Extraction.

An interventional study of 1.8 ml of 4% Articaine and 3.6 ml of 4% Articaine in Buccal Infiltration, Articaine and Anesthesia, sponsored by Qassim University. Recruiting at 2 sites in Saudi Arabia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Qassim University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth. One group receives buccal infiltration of 1.8 ml of 4% Articaine and the other group receives buccal infiltration of 3.6 ml of 4% Articaine.

Read the detailed description

The most widely and commonly used injection method for the extraction of mandibular posterior teeth is the inferior alveolar nerve block (IANB) technique. However, various complications like pain during injection, transient facial nerve paralysis, trismus, hematoma, and paresthesia are associated with the inferior alveolar nerve block technique.

Local infiltration technique has been proven as a safer and less painful anesthetic injection technique compared to IANB. Unfortunately, the dense nature of cortical bone in the mandibular posterior region hinders sufficient diffusion of anesthetic solution during infiltration. Thus, to achieve an adequate anesthesia for a painless dental extraction of mandibular posterior teeth by infiltration technique, a strong and effective local anesthetic agent having a deeper penetrating property should be used.

Articaine is one of the most widely used local anesthetic agents. It is more potent and has shown more success rate than Lidocaine and Mepivacaine in providing anesthesia in mandibular and maxillary posterior teeth by buccal infiltration diffusibility.

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth.

02

Conditions studied

  • Buccal Infiltration
  • Articaine
  • Anesthesia

Keywords

  • Buccal infiltration
  • Articaine
03

In context

Lead sponsor

Qassim University is the lead sponsor of 50 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All healthy patients () or patients with mild systemic disease with no functional limitations (ASA II)
  • Patients aged ≥ 18 years of age.
  • Patients requiring extraction of mandibular posterior teeth including grossly decayed tooth, grade I mobile tooth, root stumps and indicated for therapeutic reasons.
  • Patients not allergic to the drugs or anesthetic agents used in the surgery.

Exclusion criteria

Exclusion Criteria:

  • Acute infection at the extraction site.
  • Patients indicated for surgical extraction of teeth.
  • Patients already taking medications affecting pain assessment.
  • Pregnant patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Group A

    Buccal infiltration of 3.6 ml of 4% Articaine

    Other: 3.6 ml of 4% Articaine

  • Active comparator
    Group B

    Buccal infiltration of 1.8 ml of 4% Articaine

    Other: 1.8 ml of 4% Articaine

Interventions

  • Other1.8 ml of 4% Articaine

    Buccal infiltration of 1.8 ml of 4% Articaine

  • Other3.6 ml of 4% Articaine

    Buccal infiltration of 3.6 ml of 4% Articaine.

06

What researchers measure

Primary outcomes

  1. Intensity of pain

    VAS scale is a validated scale measuring pain with possible score range from 0 (no pain) to 100 (severe pain).

    Time frame: From reflection of mucoperiosteum till delivery of tooth out of socket.

  2. Time of onset of anesthesia

    It will be assessed by probing buccal and lingual soft tissue using a dental explorer every 2 minutes after infiltration using a standard digital stop clock.

    Time frame: upto 10 minutes

  3. Presence or absence of pain

    A 100 mm Numerical rating scale assessing intraoperative pain. Possible score ranges from 0 (no pain) to 100 (worst possible pain).

    Time frame: From reflection of mucoperiosteum till delivery of tooth out of socket.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: 1 year

Access criteria: Study protocol will be provided only if requested through proper channel with proper justification.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for May 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Oct 8, 2024
StartActual
Nov 24, 2024
Primary completionEst.
May 2, 2026
CompletionEst.
May 2, 2026
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630819
Lead sponsor
Qassim University
Responsible party
Muhammad Atif Saleem Agwan (Assistant Professor, Qassim University) — Principal investigator
First posted
Oct 8, 2024
Start date
Nov 24, 2024
Primary completion
May 2, 2026 (estimated)
Completion
May 2, 2026 (estimated)
Last update
May 29, 2025

Study contacts

Muhammad Atif S Agwan
Contact
m.abdulsaleem@qu.edu.sa
966541651713
Abdul K Azad
Contact
a.azad@qu.edu.sa
00966594914343

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion